In a 52-week trial, 85.3% of people with primary biliary cholangitis who took IQIRVO had an ALP result in the normal range, compared with 23.3% who took a placebo. The…
As reported on Business Wire, new data from Merck suggest that efinopegdutide, an investigational dual GLP-1/glucagon receptor agonist, may offer a promising new approach for treating metabolic dysfunction-associated steatohepatitis (MASH)…
About Dravet Syndrome Dravet syndrome—a rare, genetically-based disorder also known as Severe Myoclonic Epilepsy of Infancy—is characterized by epileptic seizures that begin within the first year of life, along with…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
